GRAIL shares jump after FDA briefing papers support Galleri review
GRAIL (GRAL) surged 34% on Monday to its best day since February 2025 after the FDA posted briefing papers indicating no particular concerns for Wednesday’s review of the Galleri blood test.
Shares of GRAIL Inc. S. Food and Drug Administration posted briefing papers that did not identify particular concerns ahead of Wednesday’s review of the company’s Galleri blood test. FDA reviewers did not flag major concerns in the materials released for the meeting.